References
- Tuley A , FastW. The taxonomy of covalent inhibitors. Biochemistry57(24), 3326–3337 (2018).
- Boike L , HenningNJ , NomuraDK. Advances in covalent drug discovery. Nat. Rev. Drug Discov.21(12), 881–898 (2022).
- Kim H , HwangYS , KimM , ParkSB. Recent advances in the development of covalent inhibitors. RSC Med. Chem.12(7), 1037–1045 (2021).
- Nicola G , TombergJ , PrattRFet al. Crystal structures of covalent complexes of β-lactam antibiotics with Escherichia coli penicillin-binding protein 5: toward an understanding of antibiotic specificity. Biochemistry49(37), 8094–8104 (2010).
- Lonsdale R , WardRA. Structure-based design of targeted covalent inhibitors. Chem. Soc. Rev.47(11), 3816–3830 (2018).
- Gehringer M , LauferSA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J. Med. Chem.62(12), 5673–5724 (2019).
- Lu X , SmaillJB , PattersonAV , DingK. Discovery of cysteine-targeting covalent protein kinase inhibitors. J. Med. Chem.65(1), 58–83 (2022).
- Jones LH . Design of next-generation covalent inhibitors: targeting residues beyond cysteine. Annu. Rep. Med. Chem.56, 95–134 (2021).
- Lagoutte R , PatouretR , WinssingerN. Covalent inhibitors: an opportunity for rational target selectivity. Curr. Opin. Chem. Biol.39, 54–63 (2017).
- Fu K , XieF , WangF , FuL. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol.15(1), 173 (2022).
- Huang L , GuoZ , WangF , FuL. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther.6(1), 386 (2021).
- Lanman BA , AllenJR , AllenJGet al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J. Med. Chem.63(1), 52–65 (2020).
- Péczka N , OrgovánZ , Ábrányi-BaloghP , KeserűGM. Electrophilic warheads in covalent drug discovery: an overview. Expert Opin. Drug Discov.17(4), 413–422 (2022).
- Song Z , GeY , WangCet al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer. J. Med. Chem.59(14), 6580–6594 (2016).
- Chen L , FuW , ZhengLet al. Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. J. Med. Chem.61(10), 4290–4300 (2018).
- Strelow JM . A perspective on the kinetics of covalent and irreversible inhibition. SLAS Discov.22(1), 3–20 (2017).
- Barf T , KapteinA. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem.55(14), 6243–6262 (2012).
- Zhao Z , BournePE. Progress with covalent small-molecule kinase inhibitors. Drug Discov. Today23(3), 727–735 (2018).
- Owen DR , AllertonCMN , AndersonASet al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science374(6575), 1586–1593 (2021).
- Faridoon , NgR , ZhangG , LiJJ. An update on the discovery and development of reversible covalent inhibitors. Med. Chem. Res.32(6), 1039–1062 (2023).
- Lu D , YuX , LinHet al. Applications of covalent chemistry in targeted protein degradation. Chem. Soc. Rev.51(22), 9243–9261 (2022).